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BRIEF REPORTS
Characteristics, Cardiac Involvement, and Outcomes of Multisystem
Inﬂammatory Syndrome of Childhood Associated with severe acute
respiratory syndrome coronavirus 2 Infection
Christine A. Capone, MD, MPH1,2, Anupama Subramony, MD, MBA1,2, Todd Sweberg, MD, MBA1,2, James Schneider, MD1,2,
Sareen Shah, MD1,2, Lorry Rubin, MD1,2, Charles Schleien, MD, MBA1,2, the Northwell Health COVID-19 Research Consortium,
Shilpi Epstein, MD1,2, Jennifer C. Johnson, MS, MA3, Aaron Kessel, MD, MS1,2, Nila Misra, MD1,2, Elizabeth Mitchell, MD1,2,
Nancy Palumbo, MD1,2, Sujatha Rajan, MD1,2, Josh Rocker, MD1,2, Kristy Williamson, MD1,2, and
Karina W. Davidson, PhD, MASc1,3
We report on the presentation and course of 33 children with multisystem inflammatory syndrome in children and
confirmed severe acute respiratory syndrome coronavirus 2 infection. Hemodynamic instability and cardiac
dysfunction were prominent findings, with most patients exhibiting rapid resolution following anti-inflammatory
therapy. (J Pediatr 2020;224:141-5).

S

ince the first descriptions of coronavirus disease 2019
Methods
(COVID-19) due to acute infections from the severe
acute respiratory syndrome coronavirus 2 (SARSThis case series was approved by the Northwell Health InstiCoV-2) virus in November 2019, reports have identified a
tutional Review Board. No case included in this report has
relatively low incidence of acute infections in children, who
been published previously in the medical literature or as
predominantly manifest mild respiratory
part of a multicenter registry. This is a
See related article, p 24
symptoms, with few requiring hospitalizasingle-center retrospective study of pediatric
tion or intensive care.1,2 A report from 46 North American
patients admitted to Cohen Children’s Medical Center in
Queens, New York. New York state has been the epicenter
intensive care units identified only 48 children receiving critof COVID-19 in the US, and Queens County has had the
ical care between March 14 and April 3, 2020, with 4% of chilhighest number of cases of COVID-19 of any county in
dren coming to medical attention with circulatory failure.2
New York.7
Multiple reports from Europe alerted the medical community
to a new clinical syndrome associated with SARS-CoV-2
All sequentially patients hospitalized between April 17,
infection in children.3,4 Patients were primarily presenting
2020, and May 13, 2020, with fever and an inflammatory
illness who met the CDC case definition for MIS-C were
with a febrile inflammatory disease with some features of Kaincluded.5 Importantly, all included patients were required
wasaki disease and toxic shock syndrome, with profound cardiovascular involvement. Evidence suggests that this disease is
to have a positive test for SARS-CoV-2 by detection of serum
an immunologically mediated inflammatory syndrome assoantibodies or nucleic acid from a nasopharyngeal specimen.
ciated with a previous SARS-CoV-2 infection.3
Patients with COVID-like lower respiratory tract involvement were excluded.
The Centers for Disease Control and Prevention (CDC)
Data were collected from the Enterprise electronic health
published a case definition for this syndrome, termed the
record (Sunrise Clinical Manager, Allscripts, Chicago, Illimultisystem inflammatory syndrome in children (MIS-C),
nois), and all analyses were performed using Excel (Office
associated with COVID-19;5 meanwhile, the World Health OrProfessional +13, Microsoft, Redmond, Washington). Data
ganization issued a different case definition.6 Here we describe
included patient demographic information, presenting
a large cohort of children with this COVID-19–related inflamsymptoms, respiratory support requirements, use of vasoacmatory syndrome, focusing on clinical manifestations, disease
tive medications, and initial laboratory and other test results,
severity, therapeutic interventions, and early outcomes.
including markers of inflammation and cardiac function.
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Acute kidney injury was defined by the KDIGO criteria,8 and
liver dysfunction was defined as an alanine aminotransferase
level of >80 U/L.
Left ventricular (LV) dysfunction was defined as a LV ejection fraction (LVEF) of <55% based on Boston z-scores. Mild
LV dysfunction was defined as LVEF 45%-54% (z-score,
2.0 to 4.0); moderate, as LVEF 35%-44% (z-score, 4.0
to 6.0); and severe, as LVEF <35% (z-score <-6.0). Aneurysm and dilation of a coronary artery (right coronary artery
and/or left anterior descending artery) were defined by a zscore ³2.5 and a z-score of 2.0-2.49, respectively.8
Continuous variables are summarized as median and IQR,
and categorical variables are presented as frequency.

Results
We identified 33 patients who met the CDC criteria for MISC5 and had laboratory evidence of SARS-CoV-2 infection. All
33 patients also met the World Health Organization criteria
for multisystem inflammatory syndrome in children and adolescents.6 The peak of hospitalizations occurred approximately five weeks after the peak of hospitalizations with
acute COVID-19 (Figure). The cohort was predominantly
male (n = 20; 61%), and non-Hispanic (n = 24; 73%), with
a median age of 8.6 years (IQR, 5.5-12.6 years) (Table).
Most patients were previously healthy, with the exception
of 2 patients who were overweight (6%) and 12 who had
obesity (39%). The racial/ethnic distribution compares
closely with our general in-hospital population (2019 data)
of 71% non-Hispanic and, by race, 37% white nonHispanic, 21% Black non-Hispanic,15% Asian, and 24%
other. Our region has a childhood obesity rate of 18%.
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Patients presented with a median of 4 days (IQR, 3-5 days)
of fever, and almost all (n = 32; 97%) had gastrointestinal
symptoms as well as involvement of other organ systems.
Twenty-one patients (64%) had signs and symptoms meeting
the complete criteria for Kawasaki disease. The majority of
patients meeting all the criteria had shock as well (n = 16;
76%).
Tests for inflammation showed markedly elevated values
(Table). All patients had evidence of SARS-CoV-2
infection, including a positive serology in 30 patients; the
remaining 3 came to attention before the availability of
serology testing with a positive viral nucleic acid test. Blood
cultures were negative in all patients; multiplex nucleic acid
amplification test for multiple respiratory pathogens was
negative in all patients with the exception of 1 patient
positive for influenza virus. During hospitalization, 26
patients (79%) required an intensive level of care, and 6
(18%) required mechanical ventilation. Hemodynamic
dysfunction was common; 58% of the patients had
myocardial dysfunction and 76% required vasoactive
medications. Coronary artery aneurysm and dilation were
detected in 5 (15%) and 3 (9%) patients, respectively. All
patients received intravenous immunoglobulin (IVIG),
88% received aspirin, and 70% received a corticosteroid.
After incomplete response to these initial therapies, 24%
received therapy with a biologic modifying medication.
Most patients exhibited rapid clinical improvement.
There were no deaths, and the median length of hospital
stay was 4 days (IQR, 4-8 days). At the time of hospital
discharge, mild cardiac dysfunction was still present in 9 of
19 patients who had impaired function during
hospitalization.

Figure. Weekly acute COVID-19– and MIS-C–related hospital admissions.
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Table. Demographics, clinical characteristics, and
hospital course
Variables
Demographic characteristics
Patients, n
Age, y, median, IQR
Age, y, range
Female sex, n (%)
Race, n (%)
White
Black
Asian
Other/multiracial
Unknown/declined
Ethnicity, n (%)
Hispanic
Non-Hispanic
Clinical characteristics
No underlying medical conditions (excluding obesity),
n, %
Asthma or reactive airway disease, n, %
Other, n, %*
Weight status categories, n, %
Underweight (<5th percentile)
Normal weight (5th-<85th percentile)
Overweight (85th-<95th percentile)
Obese (³95th percentile)
Presenting signs/symptoms
Duration of fever, d, median (IQR)
Neurocognitive symptoms (headache, irritability,
lethargy), n, %
Gastrointestinal symptoms (vomiting, diarrhea,
abdominal pain), n, %
Respiratory symptoms (cough, congestion, dyspnea,
sore throat), n, %
Shock (requiring vasoactive), n, %
Complete Kawasaki disease, n, %
with shock, n/N (% of category)
Hospitalization
Pediatric intensive care unit admission, n (%)
Length of stay, d, median (IQR)
Initial laboratory results
White blood cell count, K/mL, median (IQR)
Absolute lymphocyte count, K/mL, median (IQR)
Lymphopenia, n, %
Hemoglobin, g/dL, median, IQR
Platelet count, K/mL, median (IQR)
C-reactive protein (ref: <5), mg/L, median (IQR)
D-dimer (ref: <230), ng/mL, median (IQR)
Fibrinogen, mg/dL, median (IQR)
Ferritin (ref: 15-150), ng/mL, median (IQR)
Lactate dehydrogenase (ref: 135-225), U/L, median
(IQR)
INR, median (IQR)
Pro-BNP (ref: <300), pg/mL, median (IQR)
Troponin T (ref: <14), ng/L, median (IQR)
Procalcitonin (ref: <0.10), ng/mL, median (IQR)
Sodium, mmol/L, median (IQR)
ALT, U/L, median (IQR)
AST, U/L, median (IQR)
Total bilirubin, mg/dL, median (IQR)
Albumin, g/dL, median (IQR)
SARS-CoV-2 testing, n (%)
IgG positive and NAA positive
IgG positive and NAA negative
NAA positive, serology test unavailable
Organ dysfunction
Acute liver injury (ALT > 80 U/L), n, %
Acute kidney injury (KDIGO), n, %†
Requirement for oxygen or positive pressure, n, %

Value
33
8.6 (5.5-12.6)
2.2-17.0
13 (39)
3 (9)
8 (24)
3 (9)
15 (45)
4 (12)
9 (27)
24 (73)
26 (79)
5 (15)
2 (6)
3 (9)
15 (45)
2 (6)
13 (39)
4 (3-5)
19 (58)
32 (97)
17 (52)
25 (76)
21 (64)
16/21 (76)
26 (79)
4 (4-8)
9.14 (7.19-12.33)
0.80 (0.49-1.42)
27 (82)
11.2 (10.5-12.0)
154 (104-205)
206 (122-291)
1700 (958-2410)
736 (619-870)
640 (313-1192)
320 (263-419)
1.31 (1.20-1.51)
3325 (640-6776)
31 (6-78)
12.05 (2.87-24.96)
133 (131-135)
38 (30-64)
54 (36-76)
0.5 (0.4-0.6)
3.4 (3.0-3.7)
6 (18)
24 (73)
3 (9)
7 (21)
23 (70)
17 (52)
(Continued )

Table. Continued
Variables
Mechanical ventilation, n, %
Intubation days, median (IQR)
Maximal vasoactive infusion score, median (IQR)‡
Echocardiography findings
Any coronary abnormality, n (%)
Left anterior descending/right coronary artery findings,
n (%)
z-score ³2.5, n (%)
z-score 2-2.49, n (%)
Lack of tapering (z-score <2), n (%)
Any LV dysfunction, n, %
Mild (LVEF 45%-54%)
Moderate (LVEF 35%-44%)
Severe (LVEF < 35%)
Medications for MIS-C, n (%)
IVIG
Second dose IVIG
Methylprednisolone
Aspirin
Anakinra
Tocilizumab
Infliximab
Enoxaparin
Disposition
Cardiac function at discharge, n (%)
Always normal
Depressed then normalized
Mildly depressed
Status
Discharged alive, n, %

Value
6 (18)
3 (2-4)
10 (5-20)
16 (48)
5 (15)
3 (9)
8 (24)
19 (58)
11 (33)
8 (24)
0 (0)
33 (100)
11 (33)
23 (70)
29 (88)
4 (12)
3 (9)
1 (3)
14 (42)
14 (42)
10 (30)
9 (27)
33 (100)

INR, International Normalized Ratio; BNP, brain natriuretic peptide; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NAA, nucleic acid amplification; Pro-BNP,
Pro-B-type natriuretic peptide; IgG, immunoglobulin G.
*Patients with other diagnoses included 1 patient with hemodynamically insignificant ventricular septal defect and 1 patient with renal tubular acidosis.
†Creatinine >50% increase from baseline or absolute increase of 0.3 mg/dL.7
‡Vasoactive infusion score = dopamine (mg/kg/min) + dobutamine (mg/kg/
min) + 100*epinephrine (mg/kg/min) + 100*norepinephrine (mg/kg/min) + 10*milrinone (mg/
kg/min) + 10, 000*vasopressin (U/kg/min).

Discussion
Here we report 33 cases of a newly recognized inflammatory
syndrome in a single US children’s medical center that exhibits some clinical and laboratory features of Kawasaki disease and appears related to antecedent COVID-19.9 The
association with COVID-19 is supported by 2 lines of evidence: (1) all patients had COVID-19, as evidenced by the
detection of SARS-CoV-2 serum antibodies or SARS-CoV2 nasal RNA; and (2) the onset and peak occurrence of cases
followed the peak in the number of children with COVID-19
admitted to the same hospital by approximately 3 and
5.5 weeks, respectively (Figure). The latent period between
the peak of pediatric cases of COVID-19 and MIS-C
suggests that MIS-C has a postinfectious, possibly
immunologically mediated pathogenesis.10,11
Our case series shares many similarities with the smaller
international case series reported as Kawasaki-like disease
from Italy3 and the hyperinflammatory shock syndrome reported from the United Kingdom.4 Similar features include
a patient population composed of previously healthy children of similar median age manifesting fever and gastrointestinal symptoms, with the development of shock with cardiac
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dysfunction in most patients and detection of coronary abnormalities in some patients. In addition, many patients in
our cohort were overweight or obese, similar to a previous
smaller case series.4 Similar to the report of Verdoni et al,
we found a spectrum of severity, with 21% of our patients
not requiring intensive care.3 Across studies, most patients
had antibodies against SARS-CoV-2 virus, suggestive of a
postinfectious, immunologically mediated pathophysiology.
Because our patients with MIS-C demonstrated some clinical and laboratory similarities with Kawasaki disease, we
applied the principles of therapy for Kawasaki disease to
our patients. The regimen included initial treatment with
IVIG and aspirin, with the addition of corticosteroid therapy
for those with shock or at greater risk of coronary artery
aneurysm.12 Biological modifying medication was also given
to those who were unresponsive to IVIG and corticosteroids.13 This treatment protocol was associated with rapid
clinical improvement and reduction in inflammatory
markers in most patients, with no mortality. Considering
the severity of cardiocirculatory manifestations, the median
length of hospitalization of only 4 days is remarkable and
likely unique to MIS-C associated with SARS-CoV-2.
Although almost all patients had organ dysfunction, most
had resolved by hospital discharge; however, a subset of patients had coronary abnormalities and decreased cardiac
function at hospital discharge. The incidence of coronary artery aneurysms and cardiac function in convalescence will be
informed by follow-up evaluations.
Although the clinical presentation had features in common with Kawasaki disease, notable differences include the
predominance of gastrointestinal symptoms and older age
range, with a median age of 8.6 years in the patients with
MIS-C, compared with the median age of 2.5 years for patients with Kawasaki disease previously admitted to our hospital.14 The most significant clinical differences are the
markedly elevated measurements of inflammation and the
higher incidence of shock and/or impaired cardiac function
(76%) in our patients with MIS-C compared with the <3%
rate of shock reported in patients with Kawasaki disease.14,15
Thus, as discussed by Shulman,16 MIS-C may be a syndrome
distinct from Kawasaki disease.
None of the patients in our cohort developed a recognized
thrombotic event, such as a pulmonary embolus or stroke.
Hypercoagulability has been widely reported in adults with
COVID-19,17 and patients with Kawasaki disease are at risk
for coronary artery thrombosis. Our patients were treated
with aspirin, as is routine for children with Kawasaki disease;
in addition, enoxaparin was administered to patients with
significantly elevated d-dimer and fibrinogen levels along
with LV dysfunction, coronary artery involvement, or electrocardiographic changes.
A potential limitation of this study is that some patients included in this case series may in fact have had
acute COVID-19 with “cytokine storm” rather than
MIS-C, given the difficulty in differentiating these clinical
entities. However, we attempted to avoid including patients with acute COVID-19 by limiting our cases to a
144
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time period after the peak of acute COVID-19 at our center and excluding patients with lower respiratory tract
involvement, a hallmark of acute COVID-19.18 It is also
possible that some pediatric patients diagnosed with acute
COVID-19 and cytokine storm may in fact have had
MIS-C. In addition, for clarity in reporting, only cases
with confirmed coronavirus infection were included; 3
additional patients who were hospitalized during the
study period and met the criteria for MIS-C but did
not have a positive SARS-CoV-2 test were not included.
It is likely this newly described inflammatory syndrome is
related to recent COVID-19 infection. A large proportion of
patients developed shock requiring vasoactive medications,
but with supportive intensive care and anti-inflammatory
therapy, most experienced clinical improvement. Further
studies to elucidate the pathophysiological basis of MIS-C,
optimize treatment regimens, and determine the sequelae
of this syndrome are of paramount importance. n
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